Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manufacturing.
